Urothelial Cancer | Specialty

The OncLive Urology condition center page is a comprehensive resource for clinical news and expert insights on urologic cancers, including prostate cancer, bladder cancer, testicular cancer, penile cancer, and renal cell carcinoma. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in brain cancer.

FDA Approval of Perioperative Durvalumab Plus Chemo Supports the Efficacy of a Novel MIBC Management Approach

May 19th 2025

Matthew Galsky, MD, discusses the significance of the FDA approval of neoadjuvant durvalumab plus chemotherapy followed by adjuvant durvalumab in MIBC.

Dr Vlachou on the Rationale for Evaluating Perioperative Enfortumab Vedotin Plus Pembrolizumab in Upper Tract Urothelial CancerCancer

May 16th 2025

Evangelia Vlachou, MD, discusses the investigation of enfortumab vedotin plus pembrolizumab as perioperative therapy in upper tract urothelial cancer.

Dr Schmidt on the Development of Novel Treatment Delivery Approaches in Bladder Cancer

May 13th 2025

Bogdana Schmidt, MD, MPH, details the emergence of novel treatment delivery methods in bladder cancer.

BCG Shortage Warrants Treatment Shifts, New Treatment Strategies in Bladder Cancer

May 13th 2025

Bogdana Schmidt, MD, MPH, details the role of BCG in bladder cancer and navigating BCG shortages across the board during Bladder Cancer Awareness Month.

Frontline Disitamab Vedotin Plus Toripalimab Improves PFS and OS in HER2+ Metastatic Urothelial Carcinoma

May 12th 2025

Disitamab vedotin plus toripalimab improved PFS and OS vs chemotherapy in HER2-expressing metastatic urothelial carcinoma.

The OncFive: Top Oncology Articles for the Week of 5/4

May 10th 2025

A doublet is approved for KRAS-mutated ovarian cancer, T-DXd followed by THP improves pCR rates in HER2+ breast cancer, and more from OncLive.

Durvalumab Plus BCG Improves DFS in High-Risk Non–Muscle-Invasive Bladder Cancer

May 9th 2025

Durvalumab plus BCG induction and maintenance improved DFS vs BCG in these settings alone in patients with high-risk non–muscle-invasive bladder cancer.

Dr Grivas on Incorporating Perioperative Durvalumab Plus Neoadjuvant Chemo into MIBC Management

May 7th 2025

Petros Grivas, MD, PhD, details questions and considerations for integrating perioperative durvalumab plus neoadjuvant chemotherapy into MIBC management.

Contrasting Adjuvant and Perioperative Trial Designs Help Refine MIBC Management

May 7th 2025

Petros Grivas, MD, PhD, discusses data from CheckMate 274 and how emerging data from bladder cancer trials are shaping immunotherapy strategies in MIBC.

Dr Schmidt on FDA-Approved Bladder-Sparing Therapies in BCG-Refractory NMIBC

May 6th 2025

Bogdana Schmidt, MD, MPH, highlights FDA approved bladder-sparing therapies for patients with BCG-refractory non–muscle-invasive bladder cancer.

NIAGARA Trial Validates Perioperative Durvalumab Approach in MIBC

May 6th 2025

Petros Grivas, MD, PhD, discusses key findings from the NIAGARA trial and how these data support the use of perioperative durvalumab in MIBC management.

FDA Issues Refusal to File Letter for Nogapendekin Alfa Inbakicept sBLA in BCG-Unresponsive Papillary NMIBC

May 5th 2025

A meeting has been requested to address the FDA's refusal to file an sBLA for nogapendekin alfa inbakicept plus BCG in BCG-unresponsive papillary NMIBC.

Five Under 5: Top Oncology Videos for the Week of 4/27

May 4th 2025

The top 5 OncLive videos of the week cover insights in colorectal cancer, prostate cancer, myeloma, renal cell carcinoma, and urothelial carcinoma.

Real-World Data Support Nadofaragene Firadenovec Use in BCG-Unresponsive NMIBC: With Jacob Moyer, BS; and Mark D. Tyson, II, MD, MPH

May 1st 2025

Oncology Experts Highlight the Key Data and Top Abstracts From AUA 2025

May 1st 2025

Experts revisit the most intriguing abstracts and data they saw presented at the 2025 American Urological Association Annual Meeting.

Subgroup Analysis Shows No Key Differences Between High-Grade Recurrence, Cancer Progression Outcomes in BCG-Unresponsive NMIBC

April 30th 2025

Among 3 subgroups of patients with BCG-unresponsive NMIBC, no significant clinical differences were identified regarding rates of high-grade recurrence.

Cancer Vaccines Begin to Take Center Stage With Investigators Anticipating an Even Brighter Future

April 30th 2025

Expert investigators discuss the current and future landscape of cancer vaccine development in various tumor types.

Padeliporfin VTP Therapy Yields Complete Responses With Manageable Safety in Low-Grade, Upper Tract Urothelial Cancer

April 29th 2025

Padeliporfin vascular targeted photodynamic therapy was safe and generated responses in low-grade, upper tract urothelial cancer.

Dr Guerrero-Ramos on the Potential Role of TAR-200 in BCG-Unresponsive Papillary NMIBC

April 29th 2025

Felix Guerrero-Ramos, MD, PhD, discusses the potential role of TAR-200 in high-risk, BCG-unresponsive, papillary-only non–muscle-invasive bladder cancer.

Dr Ghoreifi on the Feasibility for Consolidative Surgery After Enfortumab Vedotin/Pembrolizumab in Advanced Urothelial Cancer

April 28th 2025

Alireza Ghoreifi, MD, discusses the feasibility of consolidative surgery for advanced urothelial cancer receiving pembrolizumab/enfortumab vedotin.